Genetic predisposition to iron overload: Prevalence and phenotypic expression of hemochromatosis‐associated HFE‐C282Y gene mutation

References

• Andrews N. C. Disorders of iron metabolism. N Engl J Med 1999; 341: 1986–95
   PubMed Web of Science ®Google Scholar
• Marx J. J. Iron deficiency in developed countries: prevalence, influence of lifestyle factors and hazards of prevention. Eur J Clin Nutr 1997; 51: 491–4
   PubMed Web of Science ®Google Scholar
• Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–8
   PubMed Web of Science ®Google Scholar
• Pietrangelo A. Hereditary hemochromatosis: a new look at an old disease. N Engl J Med 2004; 350: 2383–97
   PubMed Web of Science ®Google Scholar
• Adams P. C., Kertesz A. E., Valberg L. S. Clinical presentation of hemochromatosis: a changing scene. Am J Med 1991; 90: 445–9
   PubMed Web of Science ®Google Scholar
• Niederau C., Fischer R., Purschel A., Stremmel W., Haussinger D., Strohmeyer G. Long‐term survival in patients with hereditary hemochromatosis. Gastroenterology 1996; 110: 1107–19
   PubMed Web of Science ®Google Scholar
• Adams P., Brissot P., Powell L. W. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485–504
   PubMed Web of Science ®Google Scholar
• Powell L. W., Halliday J. W., Cowlishaw J. L. Relationship between serum ferritin and total body iron stores in idiopathic haemochromatosis. Gut 1978; 19: 538–42
   PubMed Web of Science ®Google Scholar
• Åsberg A., Hveem K., Thorstensen K., Ellekjter E., Kannelonning K., Fjosne U., et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand J Gastroenterol 2001; 36: 1108–5
   PubMed Web of Science ®Google Scholar
• Adams P. C., Reboussin D. M., Barton J. C., McLaren C. E., Eckfeldt J. H., McLaren G. D., et al. Hemochromatosis and iron‐overload screening in a racially diverse population. N Engl J Med 2005; 352: 1769–78
   PubMed Web of Science ®Google Scholar
• Simon M., Bourel M., Fauchet R., Genetet B. Association of HLA‐A3 and HLA‐B14 antigens with idiopathic haemochromatosis. Gut 1976; 17: 332–4
   PubMed Web of Science ®Google Scholar
• Feder J. N., Gnirke A., Thomas W., Tsuchihashi Z., Ruddy D. A., Basava A., et al. A novel MHC class I‐like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408
   PubMed Web of Science ®Google Scholar
• Pointon J. J., Wallace D., Merryweather‐Clarke A. T., Robson K. J. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000; 4: 151–61
   PubMedGoogle Scholar
• Burke W., Thomson E., Khoury M. J., McDonnell S. M., Press N., Adams P. C., et al. Hereditary hemochromatosis: gene discovery and its implications for population‐based screening. JAMA 1998; 280: 172–8
   PubMed Web of Science ®Google Scholar
• Bacon B. R., Powell L. W., Adams P. C., Kresina T. F., Hoofnagle J. H. Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999; 116: 193–207
   PubMedGoogle Scholar
• Piperno A., Sampietro M., Pietrangelo A., Arosio C., Lupica L., Montosi G., et al. Heterogeneity of hemochromatosis in Italy. Gastroenterology 1998; 114: 996–1002
   PubMed Web of Science ®Google Scholar
• Hanson E. H., Imperatore G., Burke W. HFE gene and hereditary hemochromatosis: a HuGE review. Human genome epidemiology. Am J Epidemiol 2001; 154: 193–206
   PubMed Web of Science ®Google Scholar
• Merryweather‐Clarke A. T., Pointon J. J., Shearman J. D., Robson K. J. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275–8
   PubMed Web of Science ®Google Scholar
• Merryweather‐Clarke A. T., Pointon J. J., Jouanolle A. M., Rochette J., Robson K. J. Geography of HFE C282Y and H63D mutations. Genet Test 2000; 4: 183–98
   PubMedGoogle Scholar
• Distante S., Berg J. P., Lande K., Haug E., Bell H. High prevalence of the hemochromatosis‐associated Cys282Tyr HFE gene mutation in a healthy Norwegian population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol 1999; 34: 529–34
   PubMed Web of Science ®Google Scholar
• Distante S., Berg J. P., Lande K., Haug E., Bell H. HFE gene mutation (C282Y) and phenotypic expression among a hospitalised population in a high prevalence area of haemochromatosis. Gut 2000; 47: 575–9
   PubMed Web of Science ®Google Scholar
• Distante S., Robson K. J., Graham‐Campbell J., Rnaiz‐Villena A., Brissot P., Worwood M. The origin and spread of the HFE‐C282Y haemochromatosis mutation. Hum Genet 2004; 115: 269–79
   PubMed Web of Science ®Google Scholar
• Simon M., Alexandre A., Fauchet R., Genetet B., Bourel M. The genetics of hemochromatosis. Progress in medical genetics, A. G Steinberg, A. G Bearn, A. G Motulsky, B Childs. W.B. Saunders, Philadelphia 1980; 135–68
   Google Scholar
• Olsson K. S., Ritter B. Idiopatisk hemokromatose. Tidsskrift for Nor Laegeforen 1981; 29: 101, Ref Type: Generic
   Google Scholar
• Raha‐Chowdhury R., Gruen J. R. Localisation, alleleic heterogeneity, and origins of the hemochromatosis gene. Hemochromatosis: genetics, pathophysiology, diagnosis and treatment, J. C Barton, C. Q Edwards. Cambridge University Press, Cambridge 2000; 75–90
   Google Scholar
• Burt M. J., George P. M., Upton J. D., Collett J. A., Frampton C. M., Chapman T. M., et al. The significance of haemochromatosis gene mutations in the general population: implications for screening. Gut 1998; 43: 830–6
   PubMedGoogle Scholar
• Yaouanq J. Human leucocyte antigen (HLA) association and typing in hemochromatosis. Hemochromatosis, J. C Barton, C. Q Edwards. Cambridge University Press, Cambridge 2000; 63–74
   Google Scholar
• Smith J. M., Haigh J. The hitch‐hiking effect of a favourable gene. Genet Res 1974; 23: 23–35
   PubMed Web of Science ®Google Scholar
• Moalem S., Percy M. E., Kruck T. P., Gelbart R. R. Epidemic pathogenic selection: an explanation for hereditary hemochromatosis?. Med Hypotheses 2002; 59: 325–9
   PubMed Web of Science ®Google Scholar
• De Sousa M., Porto G. The immunological system in hemochromatosis. J Hepatol 1998; 28 Suppl 1: 1–7
   PubMedGoogle Scholar
• Farid N. R., Sampson L., Noel P., Barnard J. M., Davis A. J., Hillman D. A. HLA‐D‐related (DRw) antigens in juvenile diabetes mellitus. Diabetes 1979; 28: 552–7
   PubMedGoogle Scholar
• Bell H., Thordal C., Raknerud N., Hansen T., Bosnes V., Halvorsen R., et al. Prevalence of hemochromatosis among first‐time and repeat blood donors in Norway. J Hepatol 1997; 26: 272–9
   PubMed Web of Science ®Google Scholar
• Olsson K. S., Eriksson K., Ritter B., Heedman P. A. Screening for iron overload using transferrin saturation. Acta Med Scand 1984; 215: 105–12
   PubMed Web of Science ®Google Scholar
• Karlsson M., Ikkala E., Reunanen A., Takkunen H., Vuori E., Makinen J. Prevalence of hemochromatosis in Finland. Acta Med Scand 1988; 224: 385–90
   PubMedGoogle Scholar
• Beckman L. E., Sjoberg K., Eriksson S., Beckman L. Haemochromatosis gene mutations in Finns, Swedes and Swedish Saamis. Hum Hered 2001; 52: 110–2
   PubMedGoogle Scholar
• Bulaj Z. J., Griffen L. M., Jorde L. B., Edwards C. Q., Kushner J. P. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335: 1799–805
   PubMedGoogle Scholar
• Moirand R., Guyader D., Mendler M. H., Jouanolle A. M., Le Gall J. Y., David V., et al. HFE based re‐evaluation of heterozygous hemochromatosis. Am J Med Genet 2002; 111: 356–61
   PubMedGoogle Scholar
• Olynyk J. K., Cullen D. J., Aquilia S., Rossi E., Summerville L., Powell L. W. A population‐based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718–24
   PubMed Web of Science ®Google Scholar
• Deugnier Y., Jouanolle A. M., Chaperon J., Moirand R., Pithois C., Meyer J. F., et al. Gender‐specific phenotypic expression and screening strategies in C282Y‐linked haemochromatosis: a study of 9396 French people. Br J Haematol 2002; 118: 1170–8
   PubMedGoogle Scholar
• Adams P. C., Kertesz A. E., McLaren C. E., Barr R., Bamford A., Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron‐binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000; 31: 1160–4
   PubMed Web of Science ®Google Scholar
• Jackson H. A., Carter K., Darke C., Guttridge M. G., Ravine D., Hutton R. D., et al. HFE mutations, iron deficiency and overload in 10,500 blood donors. Br J Haematol 2001 Aug; 114: 474–84
   PubMed Web of Science ®Google Scholar
• McDonnell S. M., Hover A., Gloe D., Ou C. Y., Cogswell M. E., Grummer‐Strawn L. Population‐based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri. Am J Med 1999; 107: 30–7
   PubMedGoogle Scholar
• Beutler E., Felitti V. J., Koziol J. A., Ho N. J., Gelbart T. Penetrance of 845G–> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211–8
   PubMed Web of Science ®Google Scholar
• McCune C. A., Al Jader L. N., May A., Hayes S. L., Jackson H. A., Worwood M. Hereditary haemochromatosis: only 1 % of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload. Hum Genet 2002; 111: 538–43
   PubMed Web of Science ®Google Scholar
• Olynyk J. K., Knuiman M. W., Divitini M. L., Bartholomew H. C., Cullen D. J., Powell L. W. Effects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity. J Gastroenterol Hepatol 2005; 20: 1435–41
   PubMedGoogle Scholar
• Whitfield J. B., Cullen L. M., Jazwinska E. C., Powell L. W., Heath A. C., Zhu G., et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000; 66: 1246–58
   PubMed Web of Science ®Google Scholar
• Levy J. E., Montross L. K., Andrews N. C. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest 2000; 105: 1209–16
   PubMed Web of Science ®Google Scholar
• Lee P. L., Gelbart T., West C., Halloran C., Felitti V., Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor‐1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)‐1 and ‐2, and hepcidin. Blood Cells Mol Dis 2001; 27: 783–802
   PubMed Web of Science ®Google Scholar
• Walker A. P., Wallace D. F., Partridge J., Bomford A. B., Dooley J. S. Atypical haemochromatosis: phenotypic spectrum and beta2‐microglobulin candidate gene analysis. J Med Genet 1999; 36: 537–41
   PubMed Web of Science ®Google Scholar
• Piperno A., Arosio C., Fargion S., Roetto A., Nicoli C., Girelli D., et al. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology 1996; 24: 43–6
   PubMed Web of Science ®Google Scholar
• Sachot S., Moirand R., Jouanolle A. M., Mosser J., Fergelot P., Deugnier Y., et al. Low penetrant hemochromatosis phenotype in eight families: no evidence of modifiers in the MHC region. Blood Cells Mol Dis 2001; 27: 518–29
   PubMed Web of Science ®Google Scholar
• Van Vlierberghe H., Langlois M., Delanghe J., Horsmans Y., Michielsen P., Henrion J., et al. Haptoglobin phenotype 2‐2 overrepresentation in Cys282Tyr hemochromatotic patients. J Hepatol 2001; 35: 707–11
   PubMed Web of Science ®Google Scholar
• Beutler E., Gelbart T., Lee P. Haptoglobin polymorphism and iron homeostasis. Clin Chem 2002; 48: 2232–5
   PubMedGoogle Scholar
• Tolosano E., Fagoonee S., Garuti C., Valli L., Andrews N. C., Altruda F., et al. Haptoglobin modifies the hemochromatosis phenotype in mice. Blood 2005; 15(105)3353–5
   Google Scholar
• Jacolot S., Le G. G., Scotet V., Quere I., Mura C., Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood 2004; 1(103)2835–40
   Google Scholar
• Reimao R., Porto G., De Sousa M. Stability of CD4/CD8 ratios in man: new correlation between CD4/CD8 profiles and iron overload in idiopathic haemochromatosis patients. C R Acad Sci III 1991; 313: 481–7
   PubMedGoogle Scholar
• Barton J. C., Wiener H. W., Acton R. T., Go R. C. Total blood lymphocyte counts in hemochromatosis probands with HFE C282Y homozygosity: relationship to severity of iron overload and HLA‐A and ‐B alleles and haplotypes. BMC Blood Disord 2005; 5: 5
   PubMedGoogle Scholar
• Ten Elshof A. E., Brittenham G. M., Chorney K. A., Page M. J., Gerhard G., Cable E. E., et al. Gamma delta intraepithelial lymphocytes drive tumor necrosis factor‐alpha responsiveness to intestinal iron challenge: relevance to hemochromatosis. Immunol Rev 1999; 167: 223–32
   PubMedGoogle Scholar
• Gordeuk V. R., Ballou S., Lozanski G., Brittenham G. M. Decreased concentrations of tumor necrosis factor‐alpha in supernatants of monocytes from homozygotes for hereditary hemochromatosis. Blood 1992; 79: 1855–60
   PubMed Web of Science ®Google Scholar
• Fargion S., Valenti L., Dongiovanni P., Scaccabarozzi A., Fracanzani A. L., Taioli E., et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood 2001; 97: 3707–12
   PubMed Web of Science ®Google Scholar
• Cookson S., Constantini P. K., Clare M., Underhill J. A., Bernal W., Czaja A. J., et al. Frequency and nature of cytokine gene polymorphisms in type 1 autoimmune hepatitis. Hepatology 1999; 30: 851–6
   PubMed Web of Science ®Google Scholar
• Jones D. E., Watt F. E., Grove J., Newton J. L., Daly A. K., Gregory W. L., et al. Tumour necrosis factor‐alpha promoter polymorphisms in primary biliary cirrhosis [comments]. J Hepatol 1999; 30: 232–6
   PubMedGoogle Scholar
• Distante S., Elmberg M., Foss Haug K. B., Ovstebo R., Berg J. P., Kierulf P., et al. Tumour necrosis factor alpha and its promoter polymorphisms’ role in the phenotypic expression of hemochromatosis. Scand J Gastroenterol 2003; 38: 871–7
   PubMed Web of Science ®Google Scholar
• Beutler E., Gelbart T. Tumor necrosis factor alpha promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A(C282Y) hereditary hemochromatosis mutation. Blood 2002; 100: 2268–9
   PubMed Web of Science ®Google Scholar
• Donaldson P. T. TNF gene polymorphisms in primary biliary cirrhosis: a critical appraisal. J Hepatol 1999; 31: 366–8
   PubMedGoogle Scholar
• Wilson A. G. Genetics of tumour necrosis factor (TNF) in autoimmune liver diseases: red hot or red herring?. J Hepatol 1999; 30: 331–3
   PubMedGoogle Scholar
• Piperno A., Vergani A., Malosio I., Parma L., Fossati L., Ricci A., et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998; 28: 1105–9
   PubMed Web of Science ®Google Scholar
• Thorburn D., Curry G., Spooner R., Spence E., Oien K., Halls D., et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002; 50: 248–52
   PubMed Web of Science ®Google Scholar
• Bonkovsky H. L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R. W., et al. Non‐alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non‐alcoholic steatohepatitis. J Hepatol 1999; 31: 421–9
   PubMedGoogle Scholar
• Cauza E., Peck‐Radosavljevic M., Ulrich‐Pur H., Datz C., Gschwantler M., Schoniger‐Hekele M., et al. Mutations of the HFE gene in patients with hepatocellular carcinoma. Am J Gastroenterol 2003; 98: 442–7
   PubMed Web of Science ®Google Scholar
• Distante S., Bjoro K., Hellum K. B., Myrvang B., Berg J. P., Skaug K., et al. Raised serum ferritin predicts non‐response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 269–75
   PubMedGoogle Scholar
• Olynyk J. K., Reddy K. R., Di Bisceglie A. M., Jeffers L. J., Parker T. I., Radick J. L., et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104–9
   PubMed Web of Science ®Google Scholar
• Martinelli A. L., Franco R. F., Villanova M. G., Figueiredo J. F., Secaf M., Tavella M. H., et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection?. Acta Haematol 2000; 102: 152–6
   PubMed Web of Science ®Google Scholar
• Hezode C., Cazeneuve C., Coue O., Pawlotsky J. M., Zafrani E. S., Amselem S., et al. Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology 1998; 27: 306
   PubMedGoogle Scholar
• Fillebeen C., Rivas‐Estilla A. M., Bisaillon M., Ponka P., Muckenthaler M., Hentze M. W., et al. Iron inactivates the RNA polymerase NS5B and suppresses subgenomic replication of hepatitis C Virus. J Biol Chem 2005; 11(280)9049–57
   Google Scholar
• Bell H., Berg J. P., Undlien D. E., Distante S., Raknerud N., Heier H. E., et al. The clinical expression of hemochromatosis in Oslo, Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in HFE C282Y mutation negative subjects. Scand J Gastroenterol 2000; 35: 1301–7
   PubMed Web of Science ®Google Scholar
• Scotet V., Le G. G., Merour M. C., Mercier A. Y., Chanu B., Ka C., et al. Impact of HFE genetic testing on clinical presentation of hereditary hemochromatosis: new epidemiological data. BMC Med Genet 2005; 6: 24
   PubMedGoogle Scholar
• Adams P. C. Nonexpressing homozygotes for C282Y hemochromatosis: minority or majority of cases?. Mol Genet Metab 2000; 71: 81–6
   PubMedGoogle Scholar
• Wilson J. M. G., Junger G. The principles and practice of screening for disease. Public Health Paper no. 34. Geneva, World Health Organisation
   Google Scholar
• Adams P. C. Population screening for hemochromatosis: are we finding people with a disease or a biochemical curiosity?. Semin Gastrointest Dis 2002; 13: 89–94
   PubMedGoogle Scholar
• Asberg A., Hveem K., Kruger O., Bjerve K. S. Persons with screening‐detected haemochromatosis: as healthy as the general population?. Scand J Gastroenterol 2002; 37: 719–24
   PubMed Web of Science ®Google Scholar
• Hickman P. E., Hourigan L. F., Powell L. W., Cordingley F., Dimeski G., Ormiston B., et al. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis. Gut 2000; 46: 405–9
   PubMed Web of Science ®Google Scholar
• Phatak P. D., Guzman G., Woll J. E., Robeson A., Phelps C. E. Cost‐effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994; 154: 769–76
   PubMedGoogle Scholar
• Adams P. C., Gregor J. C., Kertesz A. E., Valberg L. S. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30‐year database. Gastroenterology 1995; 109: 177–88
   PubMed Web of Science ®Google Scholar
• Asberg A., Tretli S., Hveem K., Bjerve K. S. Benefit of population‐based screening for phenotypic hemochromatosis in young men. Scand J Gastroenterol 2002; 37: 1212–9
   PubMed Web of Science ®Google Scholar
• Delatycki M. B., Allen K. J., Nisselle A. E., Collins V., Metcalfe S., du S. D., et al. Use of community genetic screening to prevent HFE‐associated hereditary haemochromatosis. Lancet 2005; 366: 314–6
   PubMedGoogle Scholar
• Larsen L. E., Ellervik C., Appleyard M., Nordestgaard B. G., Birgens H., Tybjaerg‐Hansen A. Prevalence of hemochromatosis‐associated mutations in the hemochromatosis gene in the Danish population. Ugeskr Laeger 2002; 164: 4545–7
   PubMedGoogle Scholar
• Sanchez M., Villa M., Ingelmo M., Sanz C., Bruguera M., Ascaso C., et al. Population screening for hemochromatosis: a study in 5370 Spanish blood donors. J Hepatol 2003; 38: 745–50
   PubMedGoogle Scholar